ABOLOGIX awarded a multiyear Innosuisse Innovation project

Geneva, Switzerland, Juy 24, 2020 – The joint project will allow the company to further characterize the effect of blocking JAM-C (Junction Adhesion Molecule C) in hematological malignancies. The project, to be conducted in collaboration with the Geneva University Hospitals (HUG), will receive over 500,000 CHF in the form of a grant.